0001193125-22-151004.txt : 20220616 0001193125-22-151004.hdr.sgml : 20220616 20220516090054 ACCESSION NUMBER: 0001193125-22-151004 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Neoleukin Therapeutics, Inc. CENTRAL INDEX KEY: 0001404644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-732-2133 MAIL ADDRESS: STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS, INC DATE OF NAME CHANGE: 20140128 FORMER COMPANY: FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS (USA) INC DATE OF NAME CHANGE: 20070626 CORRESP 1 filename1.htm CORRESP

NEOLEUKIN THERAPEUTICS, INC.

188 East Blaine Street

Suite 450

Seattle, WA 98102

May 16, 2022

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

 

Attention:      Jason  

Drory

Office of Life Sciences

 

  Re:

Neoleukin Therapeutics, Inc.

Registration Statement on Form S-3

Filed May 9, 2022

File No. 333-264803

Via EDGAR - Acceleration Request

Requested Date:         May 18, 2022

Requested Time:        4:00 p.m. Eastern Time

Ladies and Gentlemen:

Neoleukin Therapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.

The Registrant hereby authorizes Robert A. Freedman or Julia Forbess, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.

Sincerely,
NEOLEUKIN THERAPEUTICS, INC.
By:  

/s/ Jonathan G. Drachman

  Jonathan G. Drachman
  Chief Executive Officer

 

cc:   Robert A. Freedman, Esq.
  Julia Forbess, Esq.
  Fenwick & West LLP